MARKET

NXTC

NXTC

Nextcure
NASDAQ
12.68
-0.84
-6.21%
After Hours: 12.68 0 0.00% 16:04 03/13 EDT
OPEN
13.73
PREV CLOSE
13.52
HIGH
14.36
LOW
12.66
VOLUME
22.92K
TURNOVER
--
52 WEEK HIGH
15.74
52 WEEK LOW
2.688
MARKET CAP
45.15M
P/E (TTM)
-0.6454
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at NXTC last week (0302-0306)?
Weekly Report · 5d ago
NextCure GAAP EPS of -$19.65
Seeking Alpha · 03/06 07:47
NextCure Publishes Corporate Presentation on Targeted ADC Cancer Therapies
Reuters · 03/05 21:18
NextCure reports marginal increase in 2025 net loss
Reuters · 03/05 21:17
NextCure Q4 EPS $(0.81) Beats $(2.42) Estimate
Benzinga · 03/05 21:14
*NextCure 2025 Loss/Shr $19.65 >NXTC
Dow Jones · 03/05 21:12
*NextCure Sees Funding Oper Expenses and Cap Expenditures Into 1H of 2027 Through Proof-Of-Concept for SIM0505 >NXTC
Dow Jones · 03/05 21:11
*NextCure Expects Current Fincl Resources to Sufficient to Fund Oper Expenses and Cap Expenditures Into 1H of 2027
Dow Jones · 03/05 21:11
More
About NXTC
NextCure, Inc. is a clinical-stage biopharmaceutical company that is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of action, including antibody-drug conjugates (ADC). It focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidate, LNCB74, is designed as a B7-H4 targeted ADC to kill tumors. Its clinical oncology programs include NC410 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 that is designed to block immune suppression mediated by LAIR-1. NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells.

Webull offers NextCure Inc stock information, including NASDAQ: NXTC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NXTC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NXTC stock methods without spending real money on the virtual paper trading platform.